EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A multi-institutional retrospective cohort of adult-onset medulloblastoma in the modern era

Alipi V Bonm iD, Michael S Rutenberg, Kate E Therkelsen, John Herbst, Anurag Sanaf, Marissa A Sherwood, John Y Rhee, Tresa M McGranahan, Patrick J Cimino, L Nicolas Gonzalez Castro, Derek S Tsang, Matthias A Karajannis und 5 weitere

Neuro-Oncology Advances · 06.01.2025 · 7 (1)

DOI: 10.1093/noajnl/vdae231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 22.01.2025. Verfasst von Alipi V Bonm und 16 weiteren Autor:innen. Beteiligte Einrichtung: Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH, NCI Cancer Center Support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adult onset medulloblastoma (aMB) is a rare tumor with limited available evidence. We present a large multi-institutional retrospective cohort of aMB patients treated in the modern era, with an emphasis on understanding the role of chemotherapy at initial diagnosis.

Methods

We included 267 consecutive patients with aMB treated at 7 different institutions from 2000-present, controlling for chemotherapy regimen and cycles received.

Results

Treatment factors were highly intercorrelated with one another and with treating institution. Concurrent chemotherapy was not associated with overall survival (OS). Adjuvant chemotherapy was associated with OS on univariable analyses (HR = 0.55, P = .029) and on multivariable analysis when adjusting for risk status (HR 0.55, P = .026) but not when also adjusting for treating institution. Proton craniospinal irradiation was associated with improved survival on univariable (HR = 0.50, P = .019) and multivariable analysis adjusting for risk status (HR = 0.51, P = .024) but not when treating institution was also considered. On subgroup analysis, adjuvant chemotherapy was associated with improved survival in M0 (HR = 0.55, P = .043) but not M1 disease, in patients with subtotal resection (HR = 0.43, P = .048) but not those with GTR. Similarly, progression-free survival was improved with chemotherapy in patients with M0 (HR = 0.57, P = .032) but not M1 disease, and in patients with subtotal (HR = 0.50, P = .054) but not gross total resection.

Conclusions

There was no benefit of concurrent chemotherapy. Adjuvant chemotherapy was associated with improved overall survival and this effect was driven by select subgroups, specifically those with M0 disease and those with residual tumor. We could not confirm that these associations are independent of the treating institution.

Schlagwörter

Stichwörter der Autor:innen

adjuvant chemotherapyadult medulloblastomaconcurrent chemotherapycraniospinal radiationproton

Autor:innen und Institutionen

  • Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington, USA.
  • Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurology, Stanford University, Stanford, California, USA.
  • Department of Medical Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA.
  • Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

ORCID-Profile: Alipi V Bonm, Seema Nagpal, Jason Barber, Lynne P Taylor

Förderung

  • NCI NIH HHS
  • NIH
  • NCI Cancer Center Support
  • Memorial Sloan Kettering Cancer Center

Zitieren

APA

Bonm, A. V., Rutenberg, M. S., Therkelsen, K. E., Herbst, J., Sanaf, A., Sherwood, M. A., Rhee, J. Y., McGranahan, T. M., Cimino, P. J., Gonzalez Castro, L. N., Tsang, D. S., Karajannis, M. A., Nagpal, S., Amdur, R. J., Shih, H., Barber, J., & Taylor, L. P. (2025). A multi-institutional retrospective cohort of adult-onset medulloblastoma in the modern era. Neuro-Oncology Advances, 7(1). https://doi.org/10.1093/noajnl/vdae231

Vancouver

Bonm AV, Rutenberg MS, Therkelsen KE, Herbst J, Sanaf A, Sherwood MA, et al. A multi-institutional retrospective cohort of adult-onset medulloblastoma in the modern era. Neuro-Oncology Advances. 2025;7(1). doi:10.1093/noajnl/vdae231

BibTeX
@article{Bonm2025,
  author = {Bonm, Alipi V and Rutenberg, Michael S and Therkelsen, Kate E and Herbst, John and Sanaf, Anurag and Sherwood, Marissa A and Rhee, John Y and McGranahan, Tresa M and Cimino, Patrick J and Gonzalez Castro, L Nicolas and Tsang, Derek S and Karajannis, Matthias A and Nagpal, Seema and Amdur, Robert J and Shih, Helen and Barber, Jason and Taylor, Lynne P},
  title = {A multi-institutional retrospective cohort of adult-onset medulloblastoma in the modern era},
  journal = {Neuro-Oncology Advances},
  year = {2025},
  volume = {7},
  number = {1},
  doi = {10.1093/noajnl/vdae231}
}
Kostenlos starten →